Starting Recovery From Opioid Addiction Without Getting Clean First — How the Naltrexone Transition Works
For people who specifically want to move from opioid dependence to naltrexone, one of the biggest barriers can be the transition itself. Methadone and buprenorphine treatment can begin without completing a full opioid-free detox first. Naltrexone is different: conventional induction usually requires an opioid-free period before the antagonist is started. DeBinge is designed around helping suitable patients through that transition.
Under conventional naltrexone induction guidance, patients are generally expected to complete an opioid-free period before naltrexone is administered. This is necessary because administering an opioid antagonist too early can trigger precipitated withdrawal.
For somebody who is physically dependent on opioids, however, that requirement can become a major obstacle. They may want treatment, but the thought of enduring several opioid-free days can make the process feel impossible.
Patients who want a naltrexone-based, opioid-free treatment pathway do not need to arrive having already completed the conventional opioid-free waiting period. DeBinge medically manages that transition as part of the treatment process.
The DeBinge protocol typically uses a medically supervised four-to-five-day transition involving slow-release transdermal buprenorphine patches, followed by long-acting naltrexone implantation when the treating medical team determines that the patient is clinically ready.
For the patient, this means something very important:
The Traditional Barrier: Getting Onto Naltrexone
Standard naltrexone induction pathways usually require an opioid-free period before the medication can be started.
That requirement has an important medical purpose. Naltrexone blocks opioid receptors, and if it is administered while a person remains physically dependent on opioids, it can cause rapid and severe withdrawal.
The problem is that some patients never successfully reach the point where naltrexone can begin.
They may have tried detoxification before. They may remember the insomnia, sweating, restlessness, anxiety, pain, gastrointestinal symptoms and intense cravings.
Some manage one or two days and then return to opioid use because the withdrawal becomes too difficult.
The result is that the treatment they want remains on the other side of a barrier they cannot cross.
DeBinge changes where treatment starts
Rather than telling the patient:
DeBinge uses a different model:
For somebody who has delayed treatment because they are frightened of withdrawal, this can make treatment feel much more achievable.
Three Different Medication Pathways
In the United States, people with opioid use disorder do not have to become completely opioid-free before they can begin treatment. Methadone and buprenorphine can both be used while physical opioid dependence is still present. Naltrexone is different because conventional antagonist induction normally requires the patient to reach an opioid-free stage first.
DeBinge is not claiming that methadone or buprenorphine are inappropriate treatments. Both are established options and can be lifesaving. The specific problem DeBinge is designed to address is the transition for patients who want the naltrexone pathway but are frightened of, or have struggled with, the conventional opioid-free waiting period.
The timing and challenges are different depending on the opioid involved. Read our focused guides to Suboxone or buprenorphine to naltrexone, fentanyl to naltrexone, and methadone to naltrexone.
Using Buprenorphine to Help Stabilise the Patient
A central part of the DeBinge transition protocol is buprenorphine.
Buprenorphine is a partial opioid agonist commonly used in the treatment of opioid dependence. It binds strongly to opioid receptors and can help reduce withdrawal symptoms and cravings in appropriately selected patients.
DeBinge uses buprenorphine in transdermal patch form during the transition toward naltrexone.
The patch releases buprenorphine gradually through the skin rather than delivering the medication all at once.
This slow-release delivery is used to help stabilise the patient during the transition away from full-agonist opioids.
Why the patch matters to the patient
The purpose is not simply to introduce another medication.
The purpose is to make the transition more controlled and more manageable.
- The medication is released gradually.
- The patient is medically monitored.
- The clinical plan can be adjusted according to the patient’s response.
- Withdrawal management takes place inside the treatment pathway rather than before treatment.
For somebody who has repeatedly struggled to get through withdrawal alone, that can be a major difference.
The Typical Four-to-Five-Day Transition
The exact medical plan must always be individualised, but the DeBinge protocol typically uses a transition lasting approximately four to five days.
The important point is that this entire process forms one treatment pathway.
The patient is not sent away and told to complete a difficult opioid-free detox before returning.
Why This Can Open Treatment to More People
Fear of withdrawal is one of the reasons people postpone opioid treatment.
A person may genuinely want to stop using opioids but still continue because they know what happens physically when they stop.
That does not necessarily mean they do not want recovery.
It may mean that the withdrawal barrier has become stronger than their confidence that they can get through it.
Treatment can start while the patient still needs help transitioning away from opioids. Withdrawal becomes something the medical team helps manage rather than something the patient must prove they can endure alone.
Somebody who previously thought:
may now be able to think:
Following the Treatment Principles Developed by Dr George O’Neill
The DeBinge protocol follows treatment principles developed through the work of Dr George O’Neill, founder of the Fresh Start Recovery Programme in Western Australia.
Dr O’Neill has spent decades working in addiction treatment, opioid antagonists and sustained-release naltrexone.
His work contributed to the development and clinical use of long-acting naltrexone implants and to treatment approaches designed to help patients move from opioid dependence into sustained antagonist treatment.
Fresh Start has publicly reported treating many thousands of people through its addiction treatment programs over the years, including almost 14,000 people by 2021.
DeBinge follows this Australian treatment lineage and applies these medically managed transition principles within its Nassau treatment program.
Why that experience matters
Successful addiction treatment is not only about whether a medication works pharmacologically.
It is also about whether the patient can successfully reach the treatment in the first place and remain supported long enough to begin rebuilding their life.
That is why DeBinge treats the transition, the implant and the follow-up counselling as parts of the same program rather than separate events.
Why the Naltrexone Implant Is Part of the Program
Getting through withdrawal is only the beginning.
Detoxification alone does not remove the risk of returning to opioid use.
After the acute withdrawal phase, the patient may still experience cravings, triggers, stress, emotional difficulties and exposure to the same environments associated with previous opioid use.
This is why long-acting naltrexone is included as a central part of the DeBinge program.
Naltrexone is an opioid antagonist. It binds to opioid receptors and reduces or blocks many of the effects of opioids.
The implant is intended to support three important areas
- Cravings: naltrexone can help reduce opioid cravings in some patients.
- Relapse prevention: blocking or substantially reducing the expected opioid effect can reduce the reward associated with returning to opioid use.
- Opioid blockade and overdose-risk reduction: clinically meaningful receptor blockade can reduce opioid effects during the protected period.
Why Long-Acting Protection Matters
Daily medication requires a daily decision.
A patient must remember to take it and can decide not to take it during a period of craving or emotional distress.
Long-acting treatment reduces dependence on that daily choice.
Once the implant has been inserted and is clinically active, the patient can focus more attention on rebuilding their life rather than repeatedly making medication decisions.
- Professional counselling
- Repairing family relationships
- Returning to employment
- Developing healthier routines
- Managing triggers
- Improving physical and emotional health
- Creating a more stable recovery environment
DeBinge’s Clinical Experience With Duration
These figures represent DeBinge’s clinical experience rather than an FDA-approved duration claim for a U.S. naltrexone product.
Individual responses vary, and the precise duration and strength of opioid-receptor blockade cannot be guaranteed for an individual patient.
Why the duration matters to the patient
Recovery takes time.
Detoxification may address acute physical dependence, but it does not rebuild a person’s routines, relationships, confidence or ability to manage stress.
A long-lasting treatment is intended to provide pharmacological support while those broader changes are taking place.
One Year of Professional Counselling
The naltrexone implant is not presented as a stand-alone cure.
Addiction can involve behavioural patterns, trauma, anxiety, family conflict, social environment, stress, loneliness and many other factors that medication alone cannot resolve.
For this reason, the DeBinge program includes one year of professional counselling and follow-up support.
The benefit of combining both approaches
The implant addresses an important biological part of relapse risk.
Counselling addresses the wider behavioural, psychological and social side of recovery.
The objective is not simply:
It is:
Conventional Naltrexone Induction vs the DeBinge Pathway
| Conventional Naltrexone Induction | DeBinge Treatment Pathway |
|---|---|
| Patient generally needs to complete an opioid-free period before naltrexone is administered. | Patient can begin the DeBinge treatment process without first completing the traditional opioid-free window. |
| Withdrawal may need to be managed before antagonist treatment begins. | Withdrawal management is incorporated into the treatment pathway. |
| The patient must reach the required opioid-free stage before naltrexone starts. | Slow-release buprenorphine patches are used as part of a medically supervised transition. |
| Naltrexone begins after the required induction period. | Long-acting naltrexone implantation follows when the clinical team determines the patient is ready. |
| Long-term support varies according to provider and program. | DeBinge includes one year of professional counselling and follow-up support. |
For Families, the Difference Can Matter Just as Much
Families often become exhausted trying to help somebody detox.
They may watch repeated attempts fail because withdrawal becomes too difficult.
In the DeBinge model, the family does not have to become the detoxification team.
The goal is to bring the person into professional treatment and allow the medical team to manage the transition.
Families can focus on helping the person enter treatment rather than trying to supervise an opioid-free period at home.
The Most Important Message for Someone Afraid to Start
People living with opioid dependence sometimes believe they need to become well enough before they qualify for treatment.
But a person who cannot stop opioids without becoming unwell is precisely someone who may need medical help through that transition.
The DeBinge message is therefore straightforward:
Treatment can begin while you still need help.
Buprenorphine patches can be used to help stabilise the transition.
The clinical team manages the process.
When the patient reaches the appropriate medical stage, treatment can move to long-acting naltrexone implantation.
The implant then provides extended antagonist support intended to reduce cravings, reduce relapse risk and maintain opioid-receptor blockade during an important period of recovery.
Professional counselling then continues for one year to address the aspects of addiction that medication alone cannot.
A Different Way of Thinking About the Beginning of Recovery
There is a major difference between saying:
and saying:
For somebody who has repeatedly failed to detox alone, those two messages can represent completely different possibilities.
The DeBinge model follows treatment principles developed through the work of Dr George O’Neill and the Fresh Start Recovery Programme in Australia.
It uses a medically managed transition.
It uses slow-release buprenorphine patches as part of that transition.
It moves the patient toward long-acting naltrexone implantation.
The implant is included to provide sustained pharmacological support against cravings and relapse and to maintain clinically meaningful opioid-receptor blockade during recovery.
And the program continues with a full year of professional counselling.
The objective is to make those first days manageable enough that the patient can reach the months of recovery that come afterwards.
About DeBinge
DeBinge provides addiction treatment in Nassau, The Bahamas.
Its opioid treatment pathway can include a medically supervised transition using slow-release transdermal buprenorphine patches, followed by long-acting naltrexone implantation when clinically appropriate and one year of professional counselling and follow-up support.
The approach follows treatment principles developed through the work of Dr George O’Neill and the Fresh Start Recovery Programme in Western Australia, where sustained-release naltrexone and medically managed opioid transitions have been developed and used over several decades.
Based on DeBinge’s clinical experience in The Bahamas since 2018, the implant typically provides its strongest craving and relapse-prevention support on average 9 months, while clinically meaningful opioid-receptor blockade may persist for longer, in some patients up to about 15 months. This longer blockade may continue to reduce opioid effects and overdose risk.
Treatment is individually assessed and outcomes vary. Regulatory status varies between jurisdictions. The implant discussed here is not an FDA-approved naltrexone product in the United States.
DeBinge
Nassau, The Bahamas
debinge.com